ArticlePloS one2014
Immune humanization of immunodeficient mice using diagnostic bone marrow aspirates from carcinoma patients.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Preclinical ex vivo and in vivo models to study immunotherapy agents and their combinations as predictive tools toward the clinic.Journal for immunotherapy of cancer · 2025Review
- Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency.Nature communications · 2020Article
- Engineering a Humanised Niche to Support Human Haematopoiesis in Mice: Novel Opportunities in Modelling Cancer.Cancers · 2020Article
- Mouse models in the era of large human tumour sequencing studies.Open biology · 2018Review
- Murine stroma adopts a human-like metabolic phenotype in the PDX model of colorectal cancer and liver metastases.Oncogene · 2018Article
- Transgenic Mouse Models in Cancer Research.Frontiers in oncology · 2018Review
- Current Update of Patient-Derived Xenograft Model for Translational Breast Cancer Research.Journal of mammary gland biology and neoplasia · 2017Review
- Melanoma central nervous system metastases: current approaches, challenges, and opportunities.Pigment cell & melanoma research · 2016Review
- Humanized Mouse Xenograft Models: Narrowing the Tumor-Microenvironment Gap.Cancer research · 2016Review
- Differential effect of HLA class-I versus class-II transgenes on human T and B cell reconstitution and function in NRG mice.Scientific reports · 2016Article
- The Microbiome and Cancer: Is the 'Oncobiome' Mirage Real?Trends in cancer · 2015Article
- Prioritizing therapeutic targets using patient-derived xenograft models.Biochimica et biophysica acta · 2015Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor xenografts in immunodeficient mice, while routinely used in cancer research, preclude studying interactions of immune and cancer cells or, if humanized by allogeneic immune cells, are of limited use for tumor-immunological questions. Here, we explore a novel way to generate cancer models with an autologous humanized immune system. We demonstrate that hematopoietic stem and progenitor cells (HSPCs) from bone marrow aspirates of non-metastasized carcinoma patients, which are taken at specialized centers for diagnostic purposes, can be used to generate a human immune system in NOD-scid IL2rγ(null) (NSG) and HLA-I expressing NSG mice (NSG-HLA-A2/HHD) comprising both, lymphoid and myeloid cell lineages. Using NSG-HLA-A2/HHD mice, we show that responsive and self-tolerant human T cells develop and human antigen presenting cells can activate human T cells. As critical factors we identified the low potential of bone marrow HSPCs to engraft, generally low HSPC numbers in patient-derived bone marrow samples, cryopreservation and routes of cell administration. We provide here an optimized protocol that uses a minimum number of HSPCs, preselects high-quality bone marrow samples defined by the number of initially isolated leukocytes and intra-femoral or intra-venous injection. In conclusion, the use of diagnostic bone marrow aspirates from non-metastasized carcinoma patients for the immunological humanization of immunodeficient mice is feasible and opens the chance for individualized analyses of anti-tumoral T cell responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.